FDA Approves Cabozantinib for Advanced HCC

January 14, 2019 – The FDA has approved cabozantinib as a treatment for patients with hepatocellular carcinoma (HCC) who previously received sorafenib, according to the company developing the therapy, Exelixis. The approval was based on findings from the phase III CELESTIAL trial, in which overall survival (OS) was improved by 2.2 months with cabozantinib versus placebo. Median OS with cabozantinib was 10.2 versus 8.0 months for placebo, representing … (leggi tutto)